EU/3/20/2317: Orphan designation for the treatment in haematopoietic stem cell transplantation

Allogeneic T-cell precursors, mobilised peripheral blood-derived, ex vivo cultured

Overview

On 21 August 2020, orphan designation EU/3/20/2317 was granted by the European Commission to Smart Immune, France, for allogeneic T-cell precursors, mobilised peripheral blood-derived, ex vivo cultured (also known as HTLPs) for treatment in haematopoietic stem cell transplantation.

Key facts

Active substance
Allogeneic T-cell precursors, mobilised peripheral blood-derived, ex vivo cultured
Intended use
Treatment in haematopoietic stem cell transplantation
Orphan designation status
Positive
EU designation number
EU/3/20/2317
Date of designation
21/08/2020
Sponsor

Eligo Bioscience
Pepiniere Sante Cochin
29 Rue Du Faubourg Saint Jacques
75014 Paris
France
Tel: +33 (0)9 62 50 19 97
E-mail: contact@eligo-bioscience.com

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating